NeuroSearch to present at the JP Morgan Healthcare conference, January 2008 in San Francisco

Investor News                                                                   


NeuroSearch to present at the JP Morgan Healthcare conference, January 2008 in  
San Francisco                                                                   

NeuroSearch has been invited to present at the next annual JP Morgan Healthcare 
conference to be held on 7 - 10 January 2008 in San Francisco, US. It will be   
the 26th time, the JP Morgan Healthcare conference is being held as the largest 
and most well-attended investor conference in the healthcare industry.          

Flemming Pedersen, CEO of NeuroSearch, commented:                               
”It is of major importance to us that we have been invited to present at the JP 
Morgan conference as one out of relatively few European biopharmaceutical       
companies. It proves that NeuroSearch has now grown to reach a position among   
the largest and internationally most renowned companies in this industry.”      

NeuroSearch's presentation is scheduled for                                     
Monday 7 January 2008 at 2:30 pm (EST).                                         
to be held by CEO Flemming Pedersen.                                            

In his presentation, Flemming Pedersen will give an update on NeuroSearch's     
comprehensive pipeline, currently counting 17 drug candidates in development.   
The focus of the presentation will be on the prospects for the company's two    
Phase III programmes; ACR16 for the treatment of Huntington's disease and       
tesofensine for the treatment of obesity.                                       

A PowerPoint version of the presentation will be accessible on the company's    
website www.neurosearch.com prior to the presentation at the conference.        


Contact person:                                                                 
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate  
Communications, telephone: +45 4017 5103                                        


NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. The core business covers the development of     
novel drugs, based on a broad and well-established drug discovery platform      
focusing on ion channels and CNS disorders. A substantial part of NeuroSearch's 
activities are partner financed through a broad alliance with GlaxoSmithKline   
(GSK) and collaborations with among others Abbott and Astellas. The drug        
pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in   
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase  
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in     
partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD   
(Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in             
schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder
and Parkinson's disease (Phase I) and ABT-107 as well as ABT-560 for the        
treatment of various CNS diseases - both (Phase I) in collaboration with Abbott 
as well as NSD-644 (Phase I) in collaboration with GSK. In addition, NeuroSearch
has a broad portfolio of preclinical drug candidates and holds equity interests 
in several biotech companies.